Market Study Report LLC Companion Diagnostics Market | Page 2

Polymerase chain reaction (PCR) is projected to experience more than 18% growth in
foreseeable future. Polymerase chain reaction is well suited and most widely used DNA
replication technique. In companion diagnostic test, patient?s genomic makeup is analyzed to
predict drug response. PCR provides promising result by rapid amplification of DNA fragment.
Aforementioned factor application of PCR along with ease of use associated with this technique
will drive the segment growth.
Hospital segment was valued around USD 800 million in 2018. Availability of advanced
infrastructure and skilled healthcare professionals for drug diagnostic co-development will
augment the segment growth. Rising government support for curbing the cost associated with
chronic diseases such as cancer will further impact the hospital end user segment growth.
Some of the notable industry players operational in the companion diagnostic market include
Abbott, Agilent Technologies, bioM?rieux, Foundation Medicine, Illumina, MolecularMD
(ICON), Myriad Genetic Laboratories, Johnson & Johnson, Qiagen, Roche, Thermo Fisher
Scientific and Ventana Medical Systems. These industry players adopt strategic initiatives such
as acquisitions and new product launches to sustaining industry competition. For instance, in
July 2019, Foundation Medicine received FDA approval for FoundationOneCDx that will be
used for LYNPARZA, a first line maintenance treatment in ovarian cancer.
Table of content:
Report Content
Chapter 1. Methodology
1.1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2.
Executive Summary
2.1. Companion diagnostics industry 360 degree synopsis, 2014 - 2025